Early Release – Latent Tuberculosis Screening Using Electronic Health Record Data – Volume 26, Number 9—September 2020 – Emerging Infectious Diseases journal

og eid logo 2

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

The World Health Organization End TB Strategy aims to end the global tuberculosis (TB) epidemic by 2035 (1). The US Preventive Service Task Force (2) and Centers for Disease Control and Prevention (3) recommend screening for latent tuberculosis infection (LTBI) in populations at increased risk for infection or progression to TB disease, including foreign-born persons and former residents of countries with increased TB prevalence. Seventy-four percent of active TB cases in San Diego County, California, USA, occur among foreign-born persons, most of whom are from the Philippines, Vietnam, and Mexico; 80% result from reactivated LTBI (4). Therefore, TB elimination in the United States requires better diagnosis and treatment of LTBI, especially in foreign-born persons in areas with a low background prevalence of TB, such as San Diego County. However, the frequency of screening for LTBI in foreign-born persons is unknown.

Because medical records often lack information about country of birth, we assessed whether self-reported nationality plus preferred language is a good proxy variable for foreign birth. We used this proxy to determine LTBI screening, prevalence, and treatment rates in foreign-born persons seen at UC San Diego Health (UCSDH) Medical Center in San Diego. We searched the electronic health record (EHR) at UCSDH and validated this search by reviewing a subset of individual EHRs. The University of California San Diego Institutional Review Board approved this study.

We used the clinical data repository module of our EHR, EPIC (https://www.epic.com), to search the records of all patients who accessed care in the outpatient clinic at UCSDH at least once from March 31, 2018, through March 30, 2019, and who were determined to be at high risk for LTBI on the basis of birth country (5). We calculated the proportion of foreign-born persons screened for LTBI from the total number who met our search criteria, and we compared results using a χ2 test with a 2-sided p value of <0.05. Self-reported nationality and preferred language was used as a proxy for birth country. For example, we used Mexican nationality and Spanish language as a proxy for being born in Mexico.

A total of 8,234 persons met our search criteria, most of whom were female, were Mexican, and identified Spanish as their primary language (Table). Overall, 1,437 (17.5%) underwent LTBI screening while receiving care at UCSDH, most with the Quantiferon-TB Gold test (QIAGEN, https://www.qiagen.com). Detailed review of 250 randomly selected patient EHRs from persons who underwent LTBI screening found that 209 (83.6%) had documentation of being born, living, or spending a considerable amount of time (including frequent travel) in a TB-endemic country. A higher proportion of men (19.3%) than women (16.4%) had been screened for LTBI; otherwise, persons who were and were not screened did not differ significantly. Of those screened for LTBI, 956 (66.5%) tested negative and 379 (26.4%) positive by tuberculin skin test or Quantiferon-TB Gold test. To validate LTBI status, we reviewed 250 randomly selected EHRs of patients screened for LTBI, of whom 174 (69.6%) were determined not to have LTBI, 73 (29.2%) had newly diagnosed LTBI, and 3 (1.2%) had pulmonary TB.

To determine the proportion of patients who had LTBI, we searched the EHRs of the 8,234 patients for isoniazid, rifampin, and rifapentine prescription patterns. This search identified 184 patients who had been prescribed rifampin or isoniazid and either had completed or were still undergoing treatment. To validate the EHR search we reviewed these records. A total of 135 (73.4%) patients had been treated for LTBI and 28 (15.2%) had been or were being treated for active pulmonary TB or an atypical mycobacterial infection. The remaining 23 (11.4%) had been prescribed isoniazid or rifampin for another reason, had previously been treated for LTBI and isoniazid or rifampin was documented as a historical medication, or refused treatment. No patients had been prescribed rifapentine. Of those who began treatment for LTBI, 101 (74.8%) completed or were still undergoing treatment at the time of the study, 5 (3.7%) stopped treatment, and treatment completion was unknown for 29 (21.6%).

In our tertiary/quaternary medical center, which serves a large population of foreign-born patients, we found self-reported nationality and preferred language to be a good proxy for foreign-born persons and others who meet the US Preventive Service Task Force and Centers for Disease Control and Prevention guidelines for LTBI screening. However, our single-center study is in a unique setting and so might not reflect findings in other settings. Our proposed screening strategy might miss persons who prefer speaking English but would otherwise meet criteria for LTBI screening. This study identified missed opportunities for screening and diagnosis of LTBI among foreign-born persons; of those who had a recent diagnosis of LTBI, most were successfully treated. Improved LTBI screening, possibly with the use of routine EHR tools, is needed to end the global TB epidemic.

Dr. Jenks is an assistant clinical professor in the Department of Medicine, University of California San Diego. His primary research interests include tuberculosis and invasive fungal infections.


Suggested citation for this article: Jenks JD, Garfein RS, Zhu W, Hogarth M. Latent tuberculosis screening using electronic health record data. Emerg Infect Dis. 2020 Sep [date cited]. https://doi.org/10.3201/eid2609.191391

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *